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It is estimated that up to 40% of all head and neck paragangliomas (HNPGL) have a hereditary back-
ground with the most common mutations being found in the succinate dehydrogenase (SDH) genes. 
SDHAF2 mutation leads to the rare paraganglioma syndrome 2. The authors present the case of a 
15-year-old male patient with 2, non-secretory HNPGLs, presenting with left-sided, pulsatile tin-
nitus, and hearing loss. Imaging led to the suspicion of a jugulotympanic paraganglioma on the left, 
as well as a carotid body tumor on the right. After resection of the jugulotympanic tumor, histology 
confirmed the presence of a paraganglioma; immunohistochemistry furthermore suggested a loss of 
SDHB expression. Genetic testing revealed a rare germline, loss-of-function mutation in the SDHAF2 
gene, previously described to cause hereditary paraganglioma syndrome 2. Twenty months after the 
first operation, the patient underwent a resection of the right carotid body paraganglioma. Plasma-
free metanephrines/catecholamines always remained within the reference range; the patient is under 
regular follow-up, and his relatives will be screened. Our findings emphasize the relevance of genetic 
testing in patients with HNPGL, also with negative family history, especially when the patients pre-
sent at a young age and with multiple lesions.
© Endocrine Society 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which 
permits non-commercial reproduction and distribution of the work, in any medium, provided 
the original work is not altered or transformed in any way, and that the work is properly cited. 
For commercial re-use, please contact journals.permissions@oup.com
Key Words:  pheochromocytoma/paraganglioma, hereditary tumor syndrome, SDHAF2, 
paraganglioma syndrome
  
Head and neck paragangliomas (HNPGL) are a subtype of pheochromocytoma/
paraganglioma (Pheo/PGL) and originate from the extra-adrenal ganglia of the autono-
mous nervous system. In contrast to abdominal and thoracic Pheo/PGL, HNPGL are usu-
ally nonsecretory, exclusively have a parasympathetic origin, and only rarely metastasize 
[1]. The initial manifestation of HNPGL depends on the localization and the secretory pat-
tern of the tumor. Tinnitus and hearing loss are typical for tympanal HNPGL and should 
prompt further evaluation.
Although HNPGL may occur as sporadic tumors, it is estimated that up to 50% of all 
Pheo/PGL have a hereditary background that may influence the therapeutic strategies, 
follow-up of affected patients, and screening of family members [2, 3]. The most common 
mutations are found in the succinate dehydrogenase (SDH) genes with the highest preva-
lence of mutations in SDHD, followed by SDHB and SDHC [1].
Abbreviations: FAD, Flavin adenine dinucleotide; HNPGL, head and neck paraganglioma; MRI, magnetic resonance imaging; 
PGL2, paraganglioma syndrome 2; Pheo/PDL, pheochromocytoma/paraganglioma
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SDH is a membrane-bound, mitochondrial enzyme and part of the tricarboxylic acid 
cycle, as well as of the electron transport chain. It plays a key role in energy metabolism [4]. 
The enzymes of the tricarboxylic acid cycle in general are considered tumor suppressors, 
and mutations in the corresponding genes are associated with tumorigenesis in different 
tissues [5]. Several of the mutations associated with hereditary Pheo/PGL cause a disturbed 
cellular response to hypoxia, leading to a condition called pseudohypoxia. Interestingly also 
with actual, chronic hypoxia a high incidence of Pheo/PGL occurs. This association was 
observed in populations living in high-altitude regions, as well as in patients with cyanotic 
congenital heart disease. It suggests an etiological link between the cellular responses to 
hypoxia and the development of Pheo/PGL [6].
1. Case
A 15-year-old male patient presented with a 4-month history of pulsatile tinnitus and 
hearing loss of the left ear. The patient was normotensive, did not report spells, and plasma-
free metanephrines/catecholamines were not elevated. Family history was negative for 
tumors, the mother of the patient comes from Morocco, the father from Spain, and they are 
not consanguine.
Imaging by magnetic resonance imaging (MRI) and Ga68-DOTATATE-positron emission 
tomography-computed tomography (shown in Fig. 1) revealed a left-sided jugulotympanic 
tumor (33 × 34 mm, Fisch classification C2 De2 Di1), as well as a tumor of the right ca-
rotid body (12  × 15  mm). The jugulotympanic tumor was resected after prior emboliza-
tion and the morphological suspicion of a paraganglioma was confirmed histologically. As 
shown in Fig. 2, immunohistochemistry revealed a loss of SDHB expression with positive 
staining for SDHA in neuroendocrine cells and S100 in sustentacular cells. The result of 
the immunohistochemistry, the young age of the patient, as well as the multiplicity of the 
lesions led to the hypothesis of a hereditary tumor syndrome, although family history was 
negative.
DNA from peripheral blood (leukocytes) was isolated and targeted next-generation 
sequencing of 27 (neuro-)endocrine tumor-related (including the SDHx) genes revealed 
no pathogenic mutation in the SDHD and SDHC genes but a germline mutation in the 
SDHAF2 gene (NM_017841.2; c.232G>A).
Figure 1. (A) Preoperative magnetic resonance imaging, T1-weighted postcontrast agent: 
mass lesion of the jugular foramen (33 × 34 mm) with extension to the middle ear, af-
fecting the epi- and mesotympanum. (B) Postoperative Ga68DOTATATE-positron emis-
sion tomography-computed tomography: SSTR2-positive lesion of the right carotid body 
(12 × 15 mm, SUVmax 23.2).
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Unfortunately, after the surgery the patient experienced a complete hearing loss on 
the left without further persistent deficits. The follow-up MRI after 15 and 20  months 
documented a stable size of the residual tumor on the left and of the carotid body tumor on 
the right. Plasma-free metanephrines/catecholamines remained within the reference range. 
Twenty months after the first operation, the patient underwent a resection of the right 
carotid body paraganglioma without any complications. The patient is under regular fol-
low-up, and his relatives will be screened.
2. Discussion
This young patient presented with 2 paragangliomas of the head and neck region without 
evidence of catecholamine excess. Immunohistochemical staining for SDHB was negative; 
this investigation is a reasonable first screening, as a loss of SDHB expression is seen in the 
case of any SDHx mutation, but not in other hereditary tumor syndromes [2]. He was found 
to have a germline, missense mutation of the SDHAF2 gene on chromosome 11 in position 
12.2 at site 232 with an exchange of guanine to adenine (11q12.2 c232 G>A). This mutation 
is known to cause a loss of SDHAF2 function, leading to the hereditary paraganglioma syn-
drome 2 (PGL2), first discovered in 1982 by van Baars et al. in a Dutch family with HNPGL. 
Up to now, it was only found in 1 other family in Spain. In 2009, Hao et al. succeeded in 
identifying the underlying gene mutation [4, 5, 7].
SDHAF2 is an evolutionary highly conserved cofactor of the SDH complex. As shown in 
Fig. 3, it inserts Flavin adenine dinucleotide (FAD) into SDHA, a step necessary for a fully 
functional and stable SDH complex [4, 8].
The inheritance of PGL2 is autosomal dominant with maternal imprinting, leading to tu-
morigenesis only by paternal transmission, rendering the recognition of a hereditary cause 
more difficult [5, 9]. Given the small number of reported patients with PGL2, we assume a 
connection to the Spanish descent of the patient and recommended genetic testing for his 
father and possibly affected relatives.
Figure 2. (A) Overview of the paraganglioma (hematoxylin and eosin): sheets and nests 
of neuroendocrine cells (lower part) and foreign material (asterisk, upper part) from pre-
ceding embolization. (B) Immunohistochemistry with sustentacular cells entwisting the 
neuroendocrine cells, staining positive for S100. (C) Diffuse positivity for SDHA in the tumor 
cells. (D) Loss of SDHB expression in the tumor cells. Scale bar, 250 µm (overview), 100 µm 
(magnification).
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As in our case, patients with PGL2 usually present at a young age with multiple, benign, 
and nonsecretory HNPGL. Because of the benign nature of the tumors, the indication for 
surgery could be debated and a close follow-up might be chosen in some cases; in others, a 
radiation therapy might be an option if resection is not feasible without greater damage. 
In this patient, the tumors were threatening to cause complications because of their sheer 
size, so that an operative approach was chosen. The penetrance of tumorigenesis in affected 
individuals reaches 88% to 100% by the age of 50 years. So far, no pheochromocytomas, ab-
dominal or thoracic paragangliomas, or malignant tumors have been observed [1].
Interestingly, it seems that the Spanish family was diagnosed with more tumors per pa-
tient than the original Dutch kindred. Table 1 summarizes the available patient data. Kunst 
et al. detected 24 tumors in 11 at-risk individuals in the Netherlands, whereas Bayley et al. 
found 11 tumors in 4 family members in Spain. In addition, the average age of onset was 
slightly younger in Spain (31 years) than in the Netherlands (33 years). Whether these 
discrepancies represent an actual difference, or whether they are caused by a screening 
bias, remains to be clarified [5, 9].
Table 1. Overview on the Available Patient Data From the 2 Known PGL2 Families from the 
Netherlands and Spain, as Well as Our Patient [5,9]
Netherlands Spain Switzerland
Number of patients 11 4 1
Age at diagnosis (y) 33 (22–47) 31 (20–59) 15
Gender 50% female 75% female 100% male
Number of tumors 24 11 2
Localization CBT (17), VT (4), JTT (3) CBT (6), VT (2), JTT (2), TT (1) CBT (1), JTT (1)
Abbreviations: CBT, carotid body tumor; JTT, jugulotympanic tumor; TT, thyroid tumor; VT, vagal tumor. 
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Figure 3. Structure of the SDH complex with 2 hydrophobic units: SDHC and SDHD, an-
choring the complex within the inner mitochondrial membrane, and 2 hydrophilic proteins: 
SDHA and SDHB, forming the enzymatic active component of the complex. SDHAF1 and 2 
insert iron sulfate (Fe-S) and FAD into SDHB and SDHA, respectively. To oxidate succinate 
to fumarate, 2 electrons are transferred from succinate to FAD, leading to FADH2. The 
electrons are then passed through the Fe-S clusters and reduce ubiquinone (Q) to ubiquinol 
(QH2) [8].
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HNPGL in general are usually nonsecretory and mostly benign tumors and they occur in 
up to 50% in the context of a specific germline mutation [3].
Our findings emphasize the relevance of genetic testing in patients with HNPGL (inde-
pendent of family history), especially in patients present at young age and with multiple 
lesions. Because of the high rate of hereditary Pheo/PGL, genetic testing is recommended 
for all patients with these tumors [3, 10]. Testing algorithms with serial analysis depending 
on clinical presentation and immunohistochemistry of the tumor tissue have been proposed 
in the past. Because of the high number of susceptibility genes and the better availability 
and feasibility of next-generation sequencing, the next-generation sequencing in the PPGL 
Study Group recently published a consensus statement recommending targeted gene panels 
with a basic, extended, or comprehensive gene panel [3]. Patients with a genetically proven 
paraganglioma syndrome should undergo regular clinical, laboratory, and radiological fol-
low-up. According to the particular mutation and its specific tumor risk, the imaging mo-
dality and the examined body region can be adapted [1, 2, 6, 11]. Because there is only a 
small number of PGL2 patients, the recommendations for patients with SDHD mutation 
can be applied, for instance an MRI of the head and neck region every 18  months and 
3 yearly an MRI scans from head to pelvis [12].
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